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Table 1. Top 3 greatest challenges facingBMTnurses in today’s










Recruiting/hiring nurses 28% 12% 13% 59
Education/orientation of
new nurses
15% 21% 12% -
Staying abreast of scientific
advances in BMT
22% 25% 12% 63
Working in challenging/stressful
environment
56% 24% 8% 111
Meeting patients’ needs 18% 20% 17% -
Balancing demands of
work/personal life
20% 20% 19% 59
Resources for addressing
ethical/moral issues in BMT
12% 22% 20% -
TheWeighted Rank Score is equal to the sum of points for first, second
and third choice designations (first 5 1.00 point; second 5 0.66 point;
and third 5 0.33 point).
S242 Oral Presentationstherapy when given every 6 hours, requiring prophylaxis with
phenytoin. From 2003 to date, at Children’s Memorial Hospital
(CMH) we have a RIC regimen utilizing ODD targeted BU for
two days. In this protocol, the seizure prophylaxis has been low
ODD Lo (0.05mg/kg max 2mg) since 2005. A 0.8 mg/kg test
dose (TD) of BU infused over 3 hours is given 5-7 days prior to
the RIC. Pharmacokinetic data from blood samples during the
TD BU provided information on AUC and clearance. The
AUC from the TD BU is used to calculate the ODD of BU.
The ODD BU is infused over 3 hours on day -5 and -4 of the
HSCT. To determine if ODD Lo prophylaxis for RIC BU was
associated with a low incidence of seizures, a retrospective chart
review was preformed of 68 pediatric patients from CMH. These
patients were a subset of a prospective study of RIC (IV BU x 2
days, Fludarabine 30 mg/m2 x 5 days, 6 ATG/ECP) for HSCT
carried out between July 2003 and May 2008. 50 patients (1
month-21 years of age) received ODD Lo as seizure prophylaxis
prior to ODD BU. The average ODD BU AUC per day was
3126 umol/min (2912-7254) and the average daily dose was 3.3
mg/kg. These patients had no history of seizures and were on
no other anti-epileptic medications. No patients experienced a sei-
zure during their RIC utilizing ODD Lo prophylaxis. Indication
for HSCT was malignancy in 20 patients and non-malignant dis-
ease in 30 patients. This low dose/frequency approach to seizure
prophylaxis was not associated with an increased risk of seizures.
ODD Lo is a low cost option for seizure prophylaxis in ODD BU
RIC regimens and is aimed at limiting the sedation associated
with Lo while providing coverage during the time period BU is
highly detectable in the blood allowing for a better quality of
life for the patients, especially since many of the RIC HSCTs
are done as outpatients.TRANSPLANT NURSING ORAL:
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IDENTIFYING CHALLENGES TO THE FUTURE BMT NURSING WORK-
FORCE: HEMATOPOIETIC CELL TRANSPLANTATION IN 2020
Tierney, D.K.1, Sylvanus, T.2, De Kesel Lofthus, A.3, Denzen, E.M.3,
Murphy, E.A.3, Schmit-Pokorny, K.A.4, Neumann, J.5 1Stanford Uni-
versity Medical Center, Stanford, CA; 2University of South Florida,
Tamps, FL; 3National Marrow Donor Program, Minneapolis, MN;
4University of Nebraska Medical Center, Omaha, NE; 5University of
Texas, Houston, TX
Annually, more than 20,000 blood and marrow transplants
(BMT) are performed in the U.S. and this number is expected to
increase. Challenges to the future growth of BMT stem from the
projected nursing shortage, as identified in the 2010 IOM Report
on The Future of Nursing. The National Marrow Donor Pro-
gram sponsored the System Capacity Initiative (SCI) to assess
the ability to meet the increasing demand for BMT. The SCI con-
vened the Nursing Workforce Working Group (WG) which iden-
tified two priority challenges. The first is recruitment of BMT
nurses and the second is retention of nurses currently working in
the field.
Surveys were administered to members of the Oncology Nursing
Society and American Society of Blood andMarrowTransplantation
BMT nursing special interest groups between July and August 2010;
BMT nurses were also surveyed at the 2011 BMTTandemMeetings
(N 5 205). The survey objectives included:
– Characterize the current capacity of the U.S. BMT nursing
workforce
– Identify pathways through which nurses learned of and entered
the BMT specialty
– Assess satisfaction with the BMT specialty among nurses.
The survey was sent to an estimated 1,600 BMT nurses with
a response rate of 13% (N 5 205). Among respondents, 67% in-
dicated that their institution was planning to increase the numberof transplants performed annually. Respondents identified the
greatest challenges facing the BMT Nursing Workforce (Table 1).
In the next 5 years, many BMT nurses plan to advance their
level of nursing degree (66%); change roles within BMT (48%); re-
duce the number of hours worked (36%); and change specialties
(22%).
Based on survey results, the WG initiated programs to pro-
mote BMT nursing as a career choice and to identify stressors
and challenges in BMT nurses’ work environments that contrib-
ute to compassion fatigue and job attrition. Interest in exposing
nursing students to BMT was explored via interview at Loma
Linda Hospital and School of Nursing. An Introduction to
BMT outreach presentation was developed, targeting BSN
students.
The WG will continue to develop strategies to overcome recruit-
ment and retention challenges by developing an interdisciplinary
rounds model to address moral distress and compassion fatigue
among BMT nurses and targeted messaging for outreach to diverse
nursing communities of interest.105
IMPROVING THE QUALITY OF CARE DELIVERED TO HEALTHY RELATED
DONORS: IMPLEMENTATION OF A RELATED DONOR TEAM
Sharf, S.E.S., Friedman, A., Sharf, A., Kasow, K.A. University of North
Carolina at Chapel Hill, Chapel Hill, NC
Allogeneic donor safety remains a primary cornerstone of the
UNC Bone Marrow and Stem Cell Transplant Quality Manage-
ment Program (QMP). Requirements for the safety of the do-
nor, recipient and the cellular therapy product are detailed in
the FACT Cellular Therapy Standards and the FDA’s Good
Tissue Practice Act. To insure compliance with regulations
and donor safety, continually evaluating the care delivered to re-
lated donors is a high-priority quality initiative for our program.
During 2009-2011, our QMP audited all related donor charts
for compliance of the following: review of the health history
questionnaire, pertinent positives noted in the donor’s medical
record (MR), and required laboratory evaluations. Audits also
assessed for documentation of the physical exam, assessment
of venous access, donor’s signature on the ‘‘Release of Medical
Records’’ form, pregnancy assessment, donor eligibility in the
donor and recipient’s MR, and review of abnormal results
with the donor including follow-up recommendations. Audits
were performed biannually in 2009 and 2010 and quarterly
in 2011. Data is presented in aggregate for each year. 62
Oral Presentations S243collections were performed (2009, N 5 17; 2010, N 5 28; 2011,
N 5 17). Areas of consistent compliance were infectious disease
markers and laboratory work (essentially 100%). Areas needing
improvement included donor’s blood transfusion history
(76%), signing ‘‘Release of Medical Records’’ form (11%), con-
sent documented (70%), clearance in both recipient and donor’s
MR documented (41%, 29% respectively), and abnormal results
being reviewed with follow-up recommendations (25%). To im-
prove compliance and quality of care, a checklist was designed
to help the transplant coordinator (TC) review the required
documentation, labs, and consents needed prior to donor begin-
ning mobilization or recipient beginning preparative regimen. A
new Donor Advocacy prototype was developed and imple-
mented by our program in 2011. This model created a unique
donor medical team, comprised of a separate Related Donor
Coordinator and physician. The purpose of this model is to
avoid conflict of interest, provide unbiased care to the donor,
and provide ONE dedicated TC to care for ALL related do-
nors. With the instigation of these unique programmatic
changes, an increase in compliance with donor clearance in all
aspects, close to 100% in 2011, was obtained from medical
and regulatory perspectives. We persist in auditing quarterly
as donor standards continue to evolve.TRANSPLANT NURSING ORAL: RESEARCH106
YOUNG ADULT HEMATOPOIETIC TRANSPLANT PATIENTS’ DESCRIPTIVE
THEMES
Grant, M., Cooke, L. City of Hope, Duarte, CA
Purpose: Few studies address psychological issues for adoles-
cents and young adult (AYA) following Hematopoietic Cell
Transplantation (HCT). This study 1) describes the allogeneic
transplant experience for AYA transplant patients during the first
year following transplantation, and 2) presents AYA data ob-
tained during and following a six-part post transplant discharge
study.
Methods: The design is a mixed-methods longitudinal clinical trial
testing the effects of a standardized teaching intervention on quality
of life outcomes for allogeneic HCT patients at discharge, 3, 6, and
12 months post hospitalization. The sample consisted of 24 AYA pa-
tients, a subset of the total sample of 282 allogeneic hematopoietic
transplant patients recruited from one large medical center on the
Western Coast of the United States. The subset is divided into par-
ticipants from the intervention (N 5 10) and control (N 5 14)
groups.
Results: Quantitative Data: The mean age of AYA patients at the
time of transplant was 21.5, 11 were male and 13 were female;
13 patients were Hispanic, 19 were Caucasians, and 5 were Asian.
Most of the patients admitted for transplant had a diagnosis of
acute leukemia (83.5%), and had a sibling transplant (62.5%).
For conditioning, 70.8% of the patients had full myelosuppression,
and 29.2% had reduced intensity. Fifteen were in remission
whether it was first, second or third remission. Readmission data
and reasons for readmission will be presented.
Qualitative Data: Content analysis was used to analyze patient
comments during and following the 6-part teaching interven-
tion. Themes identified included: Sexuality/Fertility, fatigue,
depression/poor coping/habits, adherence issues, use of technol-
ogy, dependency issues, changes in roles/relationships, issues
with school/education, financial issues, family problems/issues,
religion/spirituality, fear of future, uncertainty, life, death, and
more life appreciation.
Conclusions: Young adult transplant patients have significant is-
sues, some unique to the AYA population.
Research Implications:: Findings provide useful data in treating
tailored educational approaches and support for AYAs undergoing
transplant.Clinical Implications:: The themes from the content analysis high-
light the young adult issues in the context of developmental stages for
the young adult. Clinical care using developmental stages can assist
in providing targeted education.
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SLEEP DISTURBANCES DURING HOSPITALIZATION FOLLOWING
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hacker, E.D.1, Larson, J.L.2, Ferrans, C.E.1 1University of Illinois at
Chicago, Chicago, IL; 2University of Michigan, Ann Arbor, MI
People receiving high-dose chemotherapy followed by hemato-
poietic stem cell transplantation (HSCT) frequently report sleep
disturbances during the acute phase of treatment. Although the re-
ported prevalence is high, objective documentation of disturbed
sleep patterns is lacking. This study employed subjective and ob-
jective sleep assessments to evaluate sleep patterns and examine re-
lationships among sleep patterns, quality of life, and demographic
factors. The convenience sample consisted of 40 hospitalized
HSCT patients. Each subject wore a wrist actigraph for five
days to assess sleep patterns (total sleep time, sleep onset latency,
sleep efficiency, wake after sleep onset, and number of awaken-
ings). At the end of the five-day period, subjects completed a qual-
ity of life questionnaire that included a sleep disturbance item
(EORTC QLQ C-30). Study results indicate there is a high prev-
alence of sleep disturbances during hospitalization following
HSCT. Eighty two percent of subjects reported some sleep distur-
bance. The mean total sleep time per 24-hour period was 5:41
hours (SD 5 2:21 hours) and sleep efficiency, 55% (SD 5
10%). A major sleep interval (more than 3 hours) normally occurs
within each 24-hour period; however, 35% of subjects did not ex-
perience a major sleep interval during one or more 24-hour pe-
riods. HSCT subjects older than 60 spent significantly more
time attempting to fall asleep compared to those between the
ages of 18 and 39 (p\ .05). Subjects experienced frequent awak-
enings during sleep intervals (M 5 28; SD 5 13, per 24-hour pe-
riod). Total sleep time was moderately correlated with pain (r 5
.363, p\ .05) and dyspnea (r 5 .372, p\ .05). Subjective assess-
ment of sleep negatively correlated with age (r 5 -.375, p\ .05)
and cognitive function (r 5 -.380, p\ .05) while positively corre-
lated with pain (r 5 .327, p\ .05).
Conclusions: Findings suggest that a substantial number of
HSCT patients experience sleep disturbances during the acute
phase of HSCT treatment. Reductions in total sleep time were
associated with increased pain and dyspnea. Older HSCT pa-
tients spend more time trying to fall asleep while younger pa-
tients are more likely to complain of sleep disturbances. As
sleep is an essential biological function, additional research is
needed regarding the effects of sleep disturbances on recovery
following HSCT and interventions to optimize sleep during
hospitalization.108
SUPPORTING OF PARENTS DURING THEIR CHILD’S ALLOGENEIC STEM
CELL TRANSPLANTATION DEPENDS ON THEIR PARENTAL TYPE
Larsen, H.B.1, Heilmann, C.1, Johansen, C.2, Adamsen, L.3 1Rigshospita-
let, Copenhagen, Denmark; 2Danish Cancer Society, Copenhagen, Den-
mark; 3Rigshospitalet, Copenhagen, Denmark
Background: Parents to children undergoing treatment with alloge-
neic stem cell transplantation (HSCT) are highly involved in the care
of their children. However, parents have different care approaches
and conflicts may arise when discrepancies occur between the par-
ents’ rationality and the hospital systems’ standards of care.
Materials and Methods: In the period 2007-2009, 25 parents par-
ticipated in an observational study during the child’s inpatient
